Stem cell transplant with or without CAR-T for myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares standard stem cell transplant (ASCT) versus ASCT followed by a single infusion of your own immune cells engineered to attack myeloma cells (anti-BCMA CAR-T). It is for people who are newly diagnosed and eligible for a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your doctor says you can receive a stem cell transplant (ASCT).
- You have been diagnosed with multiple myeloma.
- Your liver function tests (ALT and AST) are less than 3 times the normal upper limit.
- You are not pregnant, breastfeeding, or planning to become pregnant in the next six months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
This trial tests whether combining CAR-T cell therapy with a stem cell transplant can help treat multiple myeloma. It is for patients who have already had chemotherapy but still have some signs of disease or high-risk factors.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This trial compares a new immune cell therapy (CAR-T) with a standard stem cell transplant to see which works better for people newly diagnosed with multiple myeloma. It aims to find a more effective treatment option.
This study tests a new CAR-T cell therapy that targets a protein called BCMA on myeloma cells. It is for patients with newly diagnosed multiple myeloma who cannot have a standard stem cell transplant. The therapy is a one-time infusion of your own immune cells that are modified to attack the cancer.
Hear when a new Multiple Myeloma, Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.